---
title: "NN: Net loss of 66.2746 million yuan in the first half of 2025"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254149669.md"
description: "NN announced that in the first half of 2025, operating revenue was 144 million yuan, a year-on-year decrease of 10.95%. The net loss attributable to shareholders of the listed company was 66.2746 million yuan, compared to a net loss of 74.5672 million yuan in the same period last year. The net cash flow from operating activities was 79.7023 million yuan, a year-on-year increase of 196.98%"
datetime: "2025-08-22T10:51:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254149669.md)
  - [en](https://longbridge.com/en/news/254149669.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254149669.md)
generator: "portal-rs"
---

# NN: Net loss of 66.2746 million yuan in the first half of 2025

NN announced that its operating revenue in the first half of 2025 was 144 million yuan, a year-on-year decrease of 10.95%. The net loss attributable to shareholders of the listed company was 66.2746 million yuan, compared to a net loss of 74.5672 million yuan in the same period last year. The net cash flow generated from operating activities was 79.7023 million yuan, a year-on-year increase of 196.98%

### Related Stocks

- [605178.CN](https://longbridge.com/en/quote/605178.CN.md)

## Related News & Research

- [First Tractor schedules investor presentation on 2026 interim results](https://longbridge.com/en/news/297659449.md)
- [Biocytogen and Qilu Pharmaceutical sign agreement for VHH antibody molecule](https://longbridge.com/en/news/297892535.md)
- [03:00 ETDreame lleva la cocina inteligente a la cocina de tus sueños en IFA 2026](https://longbridge.com/en/news/298098448.md)
- [10:17 ETDarkforce™ advances toward FedRAMP High for government deployment](https://longbridge.com/en/news/297666526.md)
- [Biocytogen licenses fully human VHH antibody to Qilu Pharma in non-exclusive deal](https://longbridge.com/en/news/297781804.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**